EMERYVILLE, Calif., May 17, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE AMEX:NBY), a clinical-stage biotechnology company developing novel anti-infective products for the treatment and prevention of topical infections, today announced that it has enrolled the first patients in its global Phase 2b clinical study. The study (named BAYnovationTM) will evaluate the Company's lead compound, NVC-422, for treating adenoviral conjunctivitis, a highly contagious form of "pink eye."
